ERBB2 and breast carcinoma: This formulation, administered in breast cancer patients with locally advanced or metastatic HER-2-positive tumors at doses in the range of 8–50 mg/m2 every 4 weeks, was well tolerated without detecting serious and dose-limiting toxicities.